Matthias Guckenberger1, Michael Flentje. 1. Department of Radiation Oncology, University of Wuerzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany. guckenberg_m@klinik.uni-wuerzburg.de
Abstract
PURPOSE: The present status of intensity-modulated radiation therapy (IMRT) for treatment of localized prostate cancer is discussed. METHODS: The technological basis of IMRT and the rationale for the use in treatment of prostate cancer are described. Clinical results from the literature are presented and treatment strategies for further reduction of safety margins are outlined. RESULTS AND DISCUSSION: Multiple planning studies demonstrated the dosimetric advantage of IMRT compared to three-dimensional conformal radiotherapy. Though randomized studies are missing, retrospective studies indicate that improved dose distributions of IMRT transfer into improved rates of local control and/or lower rates of rectal toxicity. However, with standard safety margins the benefit of IMRT seems to be limited. Image guidance is considered to be essential to reduce errors of patient setup and internal motion of the prostate.
PURPOSE: The present status of intensity-modulated radiation therapy (IMRT) for treatment of localized prostate cancer is discussed. METHODS: The technological basis of IMRT and the rationale for the use in treatment of prostate cancer are described. Clinical results from the literature are presented and treatment strategies for further reduction of safety margins are outlined. RESULTS AND DISCUSSION: Multiple planning studies demonstrated the dosimetric advantage of IMRT compared to three-dimensional conformal radiotherapy. Though randomized studies are missing, retrospective studies indicate that improved dose distributions of IMRT transfer into improved rates of local control and/or lower rates of rectal toxicity. However, with standard safety margins the benefit of IMRT seems to be limited. Image guidance is considered to be essential to reduce errors of patient setup and internal motion of the prostate.
Authors: Felix Heinemann; Fred Röhner; Marianne Schmucker; Gregor Bruggmoser; Karl Henne; Anca-Ligia Grosu; Hermann Frommhold Journal: Strahlenther Onkol Date: 2009-03-28 Impact factor: 3.621
Authors: Hilke Vorwerk; Daniela Wagner; Björn Seitz; Hans Christiansen; Hendrik A Wolff; Clemens F Hess Journal: Strahlenther Onkol Date: 2009-12 Impact factor: 3.621
Authors: Junqian Xu; Peter A Humphrey; Adam S Kibel; Abraham Z Snyder; Vamsidhar R Narra; Joseph J H Ackerman; Sheng-Kwei Song Journal: Magn Reson Med Date: 2009-04 Impact factor: 4.668